Best guess? research is coming. The banking deal was put to bed. RC just "happened to choose" a firm that is strong in Biotech research, is it unreasonable to expect they will be coming out with research - REAL RESEARCH (for the first time ever) on a science that has already been tested in 400,000 to 500,000 humans with no known negative side effects and all kinds of positive reports, including with some of the world's best docs on thyroiditis.
In my opinion, now would be a good time to cover BEFORE research comes out, so I think this may be short-covering in front of coverage and the new eyeballs coming.
I assume what you are writing about, is being talked about, as well as other options. The JV option will be possible when we have clinical trial results, and that's not too far off. Remember, things happen a lot faster in Europe and at a much lower cost. Mullan was prescient on that one
The shorts will try to knock the stock down to say its not a big deal - It is, because it provides HUMNAN TRIAL DATA for the biotech buyers who require Proof before buying. It will now be on a few more radar screens and with each successful trial, the shorts will be a diminishing problem.
This is nothing new to those who have been i the stock for years and those who have consumed AC, BUT it IS new for the five institutions who bought the private placement, and it is something new for the Underwriter who now has a relationship and a very large staff of Biotech/Health Care analysts who will be free to start covering Rock Creek as soon as the “quiet period” ends. Will they? I don’t know, but RC was smart enough to choose an U/W with a Research Department – those dots connect where I come from
Will $3.7MM get them thru Phase II? I think it will get them thru the first "arm" of phase II which should provide them with enough data to find a partner. Actually, with an investment banker now on the job, the potential partners will find them.
Remember that they are located at Roskamp a facility that has resources under roof that most biotechs with billions in market cap would envy. I suspect that might just offer some possible advantages that could be beneficial to Rock Creek.
You gotta do what you gotta do. I hate selling stock down here, but if this will last us through the phase II we will then we should have the data to partner up with a pharma or biotech company and get cash without diluting shareholders. Dilution one-disease-at-a-time (in other words, you don’t dilute the stock, but you have a partner for one application) that’s just fine. But at this stage we have to keep things going until we get to the point of partners/ joint ventures/ strategic alliances/ Etc.
As for the announcement today, just as expected on Phase I, we knew going in safety was a slam dunk. The “timetable” was very useful and positive – better than expected. They say trials in Europe cost “half as much and take half as long.” Looks like going to Europe was a good choice and it’s “home turf,” in some ways, for Mullan.
As for the “action’ – it’s very positive. Huge spike up on huge volume Tuesday, (something like 66 million shares on the old stock) and then to retrace 50 %+ - , AND then to hold support at $2.68 is all very positive. As the two sides pair off, it should attract new buyers who had it hit their radar screens on Tuesday’s spike. Look for a new buying spree next week on very large volume (but short of Tuesday’s “turnaround” volume). I see this week still backing and filling, with a possible upward bias. I see next week as being very interesting. Remember, our market cap is about 1/10 of similar companies with lesser potential